US 12121540
CBL inhibitors and compositions for use in adoptive cell therapy
granted A61KA61K31/4196A61K31/454
Quick answer
US patent 12121540 (CBL inhibitors and compositions for use in adoptive cell therapy) held by NURIX THERAPEUTICS, INC. expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- NURIX THERAPEUTICS, INC.
- Grant date
- Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 48
- CPC classes
- A61K, A61K31/4196, A61K31/454, A61K31/4545, A61K31/506